Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Politics Could Get In Way Of Quick Decision On New EMA Home

Executive Summary

An early decision on the new home for the European Medicines Agency would help to minimize the level of disruption that will be involved in moving the agency from London to somewhere else in Europe when the UK leaves the EU. The EMA and the European Parliament have both called for quick resolution on this, but what you want is not always what you get.

You may also be interested in...

Suspense Continues Over Formal EMA Hosting Criteria, October Decision On New Home Likely

The criteria for cities wanting to host the European Medicines Agency post Brexit should be formally agreed in June and the agency’s new location could be decided in October. There are concerns that, if the decision is left any longer, it will be hard for the EMA to move in the time remaining before the UK leaves the EU.

Brexit: UK Could Be Asked To Foot EMA Relocation Bill; Bidding Criteria Drafted

The European Commission has produced draft Brexit negotiating directives in which it suggests that the UK should bear the cost of moving the European Medicines Agency from London to elsewhere in the EU. Meanwhile, the criteria for choosing a new host country for the EMA are expected to be discussed at a meeting of heads of state at the end of April.

Brexit: Scenario Planning Well Under Way At EMA

The EMA has outlined some of the planning that has been going on in preparation for its relocation from the UK to another EU member state as a result of Brexit, including ongoing relations with the UK regulator, the MHRA.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts